Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
- DOI
- 10.1016/s1470-2045(22)00290-x
- Published
- 2022 Jul
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-22-00290-x,
title = {Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.},
author = {Motzer RJ and Powles T and Burotto M and Escudier B and Bourlon MT and Shah AY and Suárez C and Hamzaj A and Porta C and Hocking CM and Kessler ER and Gurney H and Tomita Y and Bedke J and Zhang J and Simsek B and Scheffold C and Apolo AB and Choueiri TK},
year = {2022},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(22)00290-x},
url = {https://doi.org/10.1016/s1470-2045(22)00290-x}
}RIS
TY - JOUR TI - Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. AU - Motzer RJ AU - Powles T AU - Burotto M AU - Escudier B AU - Bourlon MT AU - Shah AY AU - Suárez C AU - Hamzaj A AU - Porta C AU - Hocking CM AU - Kessler ER AU - Gurney H AU - Tomita Y AU - Bedke J AU - Zhang J AU - Simsek B AU - Scheffold C AU - Apolo AB AU - Choueiri TK PY - 2022 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(22)00290-x UR - https://doi.org/10.1016/s1470-2045(22)00290-x ER -
APA
RJ, M., T, P., M, B., B, E., MT, B., AY, S., C, S., A, H., C, P., CM, H., ER, K., H, G., Y, T., J, B., J, Z., B, S., C, S., AB, A., & TK, C. (2022). Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(22)00290-x
Source records
- pubmed · retrieved 2026-09-26T02:47:20.812Z